CN111315378A - 包含lsz102和瑞博西尼的药物组合 - Google Patents

包含lsz102和瑞博西尼的药物组合 Download PDF

Info

Publication number
CN111315378A
CN111315378A CN201880072600.5A CN201880072600A CN111315378A CN 111315378 A CN111315378 A CN 111315378A CN 201880072600 A CN201880072600 A CN 201880072600A CN 111315378 A CN111315378 A CN 111315378A
Authority
CN
China
Prior art keywords
lsz102
day
pharmaceutically acceptable
breast cancer
mcf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880072600.5A
Other languages
English (en)
Chinese (zh)
Inventor
T·阿布拉姆斯
L·盖瑟
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN111315378A publication Critical patent/CN111315378A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201880072600.5A 2017-11-16 2018-11-14 包含lsz102和瑞博西尼的药物组合 Pending CN111315378A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762587239P 2017-11-16 2017-11-16
US62/587,239 2017-11-16
US201862758835P 2018-11-12 2018-11-12
US62/758,835 2018-11-12
PCT/IB2018/058963 WO2019097426A1 (en) 2017-11-16 2018-11-14 Pharmaceutical combination comprising lsz102 and ribociclib

Publications (1)

Publication Number Publication Date
CN111315378A true CN111315378A (zh) 2020-06-19

Family

ID=64572406

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880072600.5A Pending CN111315378A (zh) 2017-11-16 2018-11-14 包含lsz102和瑞博西尼的药物组合

Country Status (6)

Country Link
US (2) US11179365B2 (https=)
EP (1) EP3709997A1 (https=)
JP (1) JP2021503448A (https=)
CN (1) CN111315378A (https=)
TW (1) TW201922238A (https=)
WO (1) WO2019097426A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023284790A1 (zh) * 2021-07-13 2023-01-19 江苏恒瑞医药股份有限公司 选择性雌激素受体共价拮抗剂与cdk4/6抑制剂联合在制备治疗乳腺癌药物中的用途

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105828822B (zh) 2013-08-14 2019-10-18 诺华股份有限公司 用于治疗癌症的组合疗法
CN111386113A (zh) * 2017-12-01 2020-07-07 诺华股份有限公司 包含lsz102和阿培利司的药物组合

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017172957A1 (en) * 2016-04-01 2017-10-05 Kalyra Pharmaceuticals, Inc. Estrogen receptor modulators

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080306057A1 (en) 2005-10-11 2008-12-11 Laboratories Serono Sa P13K Inhibitors for the Treatment of Endometriosis
ES2522346T3 (es) 2008-08-22 2014-11-14 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de CDK
EP2650401A1 (de) 2012-04-10 2013-10-16 Siemens Aktiengesellschaft Kraftwerk basiertes Methanisierungssystem
ES2671516T3 (es) * 2013-02-19 2018-06-06 Novartis Ag Derivados de benzotiofeno y composiciones de los mismos como degradantes selectivos de los receptores de estrógeno
EP3696276A1 (en) * 2013-02-25 2020-08-19 Novartis AG Novel androgen receptor mutation
EA031077B1 (ru) 2013-06-19 2018-11-30 Серагон Фармасьютикалз, Инк. Модулятор рецептора эстрогена и его применения
WO2014203129A1 (en) * 2013-06-19 2014-12-24 Olema Pharmaceuticals, Inc. Combinations of benzopyran compounds, compositions and uses thereof
CN105828822B (zh) 2013-08-14 2019-10-18 诺华股份有限公司 用于治疗癌症的组合疗法
WO2015028409A1 (de) 2013-08-27 2015-03-05 Bayer Pharma Aktiengesellschaft 6,7-dihydro-5h-benzo[7]annulen-derivate, verfahren zu ihrer herstellung, pharmazeutische präparate die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln
JP6223154B2 (ja) 2013-11-29 2017-11-01 ロッテ アドバンスト マテリアルズ カンパニー リミテッド ポリアミド樹脂およびその製造方法
WO2015136016A2 (en) 2014-03-13 2015-09-17 F. Hoffmann-La Roche Ag Therapeutic combinations with estrogen receptor modulators
KR20250152679A (ko) 2015-04-29 2025-10-23 래디어스 파마슈티컬스, 인코포레이티드 암을 치료하는 방법
HK1249866A1 (zh) 2015-06-29 2018-11-16 豪夫迈‧罗氏有限公司 用他塞利昔布进行治疗的方法
WO2017168303A1 (en) 2016-03-29 2017-10-05 Novartis Ag Reaction medium containing water-surfactant mixture
EP3440067B1 (en) * 2016-04-08 2021-05-26 F. Hoffmann-La Roche AG Tetrahydroisoquinoline estrogen receptor modulators and uses thereof
MX2019008158A (es) 2017-01-06 2019-12-09 G1 Therapeutics Inc Terapia de combinacion para el tratamiento del cancer.
CN111386113A (zh) 2017-12-01 2020-07-07 诺华股份有限公司 包含lsz102和阿培利司的药物组合

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017172957A1 (en) * 2016-04-01 2017-10-05 Kalyra Pharmaceuticals, Inc. Estrogen receptor modulators

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
NCT02734615: "NCT02734615", 《NCT02734615》 *
S. P. CORONA ET AL.,: "Advances in systemic therapy for metastatic breast cancer: future perspectives", 《MEDICAL ONCOLOGY》 *
SUZANNE E. WARDELL ET AL.,: "Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy–Resistant Breast Cancer", 《CLINICAL CANCER RESEARCH》 *
陈本川: "治疗晚期乳腺癌新药——瑞博西尼（ribociclib）", 《医药导报》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023284790A1 (zh) * 2021-07-13 2023-01-19 江苏恒瑞医药股份有限公司 选择性雌激素受体共价拮抗剂与cdk4/6抑制剂联合在制备治疗乳腺癌药物中的用途

Also Published As

Publication number Publication date
US20190142796A1 (en) 2019-05-16
TW201922238A (zh) 2019-06-16
EP3709997A1 (en) 2020-09-23
JP2021503448A (ja) 2021-02-12
WO2019097426A1 (en) 2019-05-23
US20220031657A1 (en) 2022-02-03
US11179365B2 (en) 2021-11-23

Similar Documents

Publication Publication Date Title
TWI831916B (zh) 包含tno155和瑞博西尼之藥物組合
US10695333B2 (en) Pharmaceutical combination comprising LSZ102 and alpelisib
JP6595024B2 (ja) Ｂ−Ｒａｆ阻害薬、ＥＧＦＲ阻害薬及び場合によってはＰＩ３Ｋ−α阻害薬を含む組合せ医薬
US20070161690A1 (en) Compounds and methods for inhibiting the interaction of BCL proteins with binding partners
US20220031657A1 (en) Pharmaceutical combination comprising lsz102 and ribociclib
WO2023225283A1 (en) Treatments with nirogacestat
US11083722B2 (en) Combination therapies for the treatment of breast cancer
US20210121460A1 (en) A triple pharmaceutical combination comprising dabrafenib, trametinib and an erk inhibitor
TW202339726A (zh) 用於治療癌症之與畢尼替尼(Binimetinib)併用之HDAC抑制劑OKI-179
CN117177752A (zh) 用于治疗mpnst的化合物和组合物
RU2813111C2 (ru) Фармацевтическая комбинация, содержащая tno155 и рибоциклиб
AU2024304092A1 (en) Use of akt inhibitor in preparation of drug for preventing or treating breast cancer
HK40121691A (zh) 治疗cdk4/6抑制剂耐药性癌症的方法
HK40127185A (zh) 雌激素受体降解剂的给药方案

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20200619

WD01 Invention patent application deemed withdrawn after publication